<?xml version='1.0' encoding='utf-8'?>
<document id="31274208"><sentence text="Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib."><entity charOffset="46-58" id="DDI-PubMed.31274208.s1.e0" text="Capecitabine" /><entity charOffset="83-92" id="DDI-PubMed.31274208.s1.e1" text="Celecoxib" /><pair ddi="false" e1="DDI-PubMed.31274208.s1.e0" e2="DDI-PubMed.31274208.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31274208.s1.e0" e2="DDI-PubMed.31274208.s1.e1" /></sentence><sentence text="This study investigated the time course and magnitude of the pharmacokinetic interaction between capecitabine and the cytochrome P450 (CYP) 2C9 substrate celecoxib, with implications for coadministration of fluoropyrimidines with CYP2C9 substrates such as warfarin"><entity charOffset="97-109" id="DDI-PubMed.31274208.s2.e0" text="capecitabine" /><entity charOffset="154-163" id="DDI-PubMed.31274208.s2.e1" text="celecoxib" /><entity charOffset="207-224" id="DDI-PubMed.31274208.s2.e2" text="fluoropyrimidines" /><entity charOffset="256-264" id="DDI-PubMed.31274208.s2.e3" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.31274208.s2.e0" e2="DDI-PubMed.31274208.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31274208.s2.e0" e2="DDI-PubMed.31274208.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31274208.s2.e0" e2="DDI-PubMed.31274208.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31274208.s2.e0" e2="DDI-PubMed.31274208.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31274208.s2.e1" e2="DDI-PubMed.31274208.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31274208.s2.e1" e2="DDI-PubMed.31274208.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31274208.s2.e1" e2="DDI-PubMed.31274208.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31274208.s2.e2" e2="DDI-PubMed.31274208.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31274208.s2.e2" e2="DDI-PubMed.31274208.s2.e3" /></sentence><sentence text=" Patients received celecoxib 200 mg orally twice daily continuously, with capecitabine (1000 mg/m2 orally twice daily for 14 days every 21 days) starting 7 days later"><entity charOffset="19-28" id="DDI-PubMed.31274208.s3.e0" text="celecoxib" /><entity charOffset="74-86" id="DDI-PubMed.31274208.s3.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.31274208.s3.e0" e2="DDI-PubMed.31274208.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31274208.s3.e0" e2="DDI-PubMed.31274208.s3.e1" /></sentence><sentence text=" Assessment of the drug-drug interaction (DDI) potential was performed using equivalence testing, which assumes that there is no clinically relevant DDI when the calculated 90% confidence intervals (CIs) of the drug exposure ratios fall within the range of 0" /><sentence text="80 to 1" /><sentence text="25" /><sentence text=" Comparison of steady-state pharmacokinetic parameters of celecoxib between day 7 (cycle 0, celecoxib only) and day 14 (cycle 1, celecoxib + capecitabine) showed geometric mean ratios of 1"><entity charOffset="58-67" id="DDI-PubMed.31274208.s7.e0" text="celecoxib" /><entity charOffset="92-101" id="DDI-PubMed.31274208.s7.e1" text="celecoxib" /><pair ddi="false" e1="DDI-PubMed.31274208.s7.e0" e2="DDI-PubMed.31274208.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31274208.s7.e0" e2="DDI-PubMed.31274208.s7.e1" /></sentence><sentence text="24 (90%CI, 1" /><sentence text="04-1" /><sentence text="49), 1" /><sentence text="30 (1" /><sentence text="11-1" /><sentence text="53) and 1" /><sentence text="28 (1" /><sentence text="11-1" /><sentence text="47) for maximum plasma concentration, minimum plasma concentration, and area under the concentration-time curve from time zero to 8 hours, respectively" /><sentence text=" Comparison of day 7 vs day 21 (cycle 1, after 1 week washout of capecitabine) showed a further increase in the geometric mean ratio of maximum plasma concentration (1"><entity charOffset="65-77" id="DDI-PubMed.31274208.s17.e0" text="capecitabine" /></sentence><sentence text="39; 90%CI, 1" /><sentence text="16-1" /><sentence text="66), minimum plasma concentration (1" /><sentence text="53; 1" /><sentence text="10-2" /><sentence text="12) and area under the concentration-time curve from time zero to 8 hours (1" /><sentence text="41; 1" /><sentence text="19-1" /><sentence text="68)" /><sentence text=" Because the 90%CIs fell outside the prespecified equivalence margin, we conclude that coadministration results in a DDI (increased celecoxib exposure) that persists for at least 7 days after capecitabine discontinuation"><entity charOffset="132-141" id="DDI-PubMed.31274208.s27.e0" text="celecoxib" /><entity charOffset="192-204" id="DDI-PubMed.31274208.s27.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.31274208.s27.e0" e2="DDI-PubMed.31274208.s27.e0" /><pair ddi="false" e1="DDI-PubMed.31274208.s27.e0" e2="DDI-PubMed.31274208.s27.e1" /></sentence><sentence text=" Close monitoring should be undertaken when administering fluoropyrimidines with CYP2C9 substrates with narrow therapeutic indexes while also weighing the benefits and risks for individual patients"><entity charOffset="58-75" id="DDI-PubMed.31274208.s28.e0" text="fluoropyrimidines" /></sentence><sentence text="" /></document>